Loading
A phase 3 trial of FAP-2286 in prostate cancer, run by Novartis Pharmaceuticals, now recruiting.
An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC. is a phase 3 interventional study registered as NCT05939414 by Novartis Pharmaceuticals, with 450 participants planned, started 2024-03-12 and due to reach its primary completion in 2028-04-25. Interventions recorded: AAA617, piflufolastat (18F), gallium (68Ga) gozetotide (25μg). Conditions listed: Oligometastatic Prostate Cancer (OMPC). No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares FAP-2286 (177Lu / 68Ga), FAPI PET, Radioligand therapy (beta emitters).
Shares FAP-2286 (177Lu / 68Ga), FAPI PET, Radioligand therapy (beta emitters), Prostate cancer.
Shares FAP-2286 (177Lu / 68Ga), Novartis, Prostate cancer.
Shares FAP-2286 (177Lu / 68Ga), FAPI PET, Radioligand therapy (beta emitters).
Shares Radioligand therapy (beta emitters), Novartis, Prostate cancer.
Shares FAP-2286 (177Lu / 68Ga), Novartis.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/